Onkos Surgical, a Parsippany, NJ-based company developing technologies for the musculoskeletal space, received $35M in Venture Loan Facility from Horizon Technology Finance Corporation (NASDAQ: HRZN).
Led by CEO Patrick Treacy, Onkos Surgical is an innovator in the musculoskeletal space, developing technologies to address the clinical challenges associated with complex orthopaedic procedures. Its portfolio of products provides solutions for adult and pediatric patients who have bone loss from tumor, trauma, or revision of failed orthopaedic implants.
In April 2024, NanoCept was granted the first-ever FDA De Novo authorization for an antibacterial coating technology used on orthopaedic implants, demonstrating Onkos’s innovation capabilities.
The company intends to use the proceeds of the loan facility to accelerate manufacturing and commercialization of NanoCept™, an antibacterial coating technology that is used on FDA-granted orthopaedic implants to reduce bacterial contamination at the time of implantation.
FinSMEs
08/01/2025